دورية أكاديمية
أعرض في EDS

Red blood cell alloimmunisation in sickle cell disease patients in the Democratic Republic of the Congo.

التفاصيل البيبلوغرافية
العنوان: Red blood cell alloimmunisation in sickle cell disease patients in the Democratic Republic of the Congo.
المؤلفون: Kambale-Kombi P; Département de Médecine interne, Faculté de Médecine et de Pharmacie, Université de Kisangani, Kisangani, Democratic Republic of the Congo., Djang'eing'a RM; Département des Sciences Pharmaceutiques, Laboratoire de chimie analytique, Faculté de Médecine, Université de Liège, Liège, Belgium., Alworong'a Opara JP; Département de Pédiatrie, Faculté de Médecine et de Pharmacie, Université de Kisangani, Kisangani, Democratic Republic of the Congo., Minon JM; Département de Thrombose-hémostase et Transfusion, Centre Hospitalier Régional de la Citadelle, Liège, Belgium., Sepulchre E; Département de Thrombose-hémostase et Transfusion, Centre Hospitalier Régional de la Citadelle, Liège, Belgium., Bours V; Département de Génétique Humaine, Faculté de Médecine, Université de Liège, Liège, Belgium., Floch A; Etablissement français du sang(EFS) Ile-de-France, Créteil, France.; Univ Paris Est Créteil, INSERM U955 Equipe 2 « Transfusion et maladies du globule », IMRB, Créteil, France., Pirenne F; Etablissement français du sang(EFS) Ile-de-France, Créteil, France.; Univ Paris Est Créteil, INSERM U955 Equipe 2 « Transfusion et maladies du globule », IMRB, Créteil, France., Tshilumba CK; Département de Médecine interne, Faculté de Médecine et de Pharmacie, Université de Kisangani, Kisangani, Democratic Republic of the Congo., Batina-Agasa S; Département de Médecine interne, Faculté de Médecine et de Pharmacie, Université de Kisangani, Kisangani, Democratic Republic of the Congo.
المصدر: Transfusion medicine (Oxford, England) [Transfus Med] 2023 Apr; Vol. 33 (2), pp. 137-146. Date of Electronic Publication: 2022 Nov 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9301182 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-3148 (Electronic) Linking ISSN: 09587578 NLM ISO Abbreviation: Transfus Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford ; Boston : Blackwell Scientific Publications,
مواضيع طبية MeSH: Anemia, Sickle Cell*/epidemiology , Anemia, Sickle Cell*/therapy , Anemia, Hemolytic, Autoimmune* , Blood Group Antigens*, Humans ; Child, Preschool ; Child ; Adolescent ; Young Adult ; Adult ; Democratic Republic of the Congo/epidemiology ; Cross-Sectional Studies ; Erythrocytes ; Blood Transfusion ; Isoantibodies
مستخلص: Objectives: To determine the prevalence of red blood cell (RBC) alloimmunisation and alloantibody specificity in sickle cell disease (SCD) patients in Kisangani, Democratic Republic of Congo (DRC) in comparison with those followed at the Centre Hospitalier Régional (CHR) de la Citadelle of Liège (Belgium).
Background: Data regarding RBC alloimmunisation (immune response of the organism to foreign erythrocyte antigens, antigens that lack on its own RBC) in SCD patients are scarce in sub-Saharan Africa.
Methods: We conducted a multi-site-based cross-sectional study among 125 SCD patients at Kisangani and 136 at the CHR de la Citadelle of Liège. The diagnosis of SCD was confirmed by high-performance liquid chromatography. Alloantibodies were screened using the agglutination technique on gel cards and their specificity determined using 11 and/or 16 cell panels. Statistical analyses were carried out using SPSS.
Results: The prevalence of RBC alloimmunisation was 9.6% among SCD patients in Kisangani versus 22.8% in those of Liège. At Kisangani as well as at Liège, the median age of alloimmunised patients was higher than that of non-alloimmunised patients, 15.5 years (IQR:4.8-19.8) and 24 years (IQR:14-31) versus 10 years (IQR: 6.5-17) and 17 years (IQR:12-24), respectively. The median number of blood units was higher in both Kisangani and Liège immunised patients compared to non-immunised patients, 8 (IQR:5-11) versus 5 (IQR:3-13) and 41(IQR:6-93) versus 6.5(3-37) respectively. At Kisangani (N = 14), the most frequent antibodies were anti-D (28.6%) and anti-C versus anti-E (13.6%), anti-S (13.6%) and anti-Lea (11.4%) at Liège (N = 44).
Conclusions: These findings stated that alloimmunisation is a common complication in SCD patients in the DRC. In the resource-limited setting of this country, blood transfusion with minimal ABO, D, C and E antigen matching in addition to the use of compatibility test could significantly reduce the incidence of this complication.
(© 2022 British Blood Transfusion Society.)
References: Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017;376(16):1561-1573.
Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2019;380(2):121-131.
Bernaudin F, Dalle JH, Bories D, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020;105(1):91-101.
Adams RJ, Brambilla D. Optimizing primary stroke prevention in sickle cell anemia (STOP 2) trial investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769-2778.
Chou ST, Fasano RM. Management of Patients with sickle cell disease using transfusion therapy: guidelines and complications. Hematol Oncol Clin North Am. 2016;30(3):591-608.
Linder GE, Chou ST. Red cell transfusion and alloimmunization in sickle cell disease. Haematologica. 2021;106(7):1805-1815.
Telen MJ, Afenyi-Annan A, Garrett ME, Combs MR, Orringer EP, Ashley-Koch AE. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion. 2015;55(6 Pt 2):1378-1387.
Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062-1071.
Yee M, Josephson CD, Winkler AM, et al. Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia. Transfusion. 2017;57(11):2738-2746.
Chou ST, Alsawas M, Fasano RM, et al. American society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327-355.
Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol. 2012;159(4):394-404.
Kambale-Kombi P, Marini Djang'eing'a R, Alworong'a Opara JP, et al. Management of sickle cell disease: current practices and challenges in a northeastern region of The Democratic Republic of the Congo. Hematology. 2021;26(1):199-205.
Kabinda Maotela J, Ramazani SY, Misingi P, Dramaix-Wilmet M. Transfusion sanguine en République démocratique du Congo: efforts réalisés et défis à relever [Blood transfusion in the Democratic Republic of Congo: efforts and challenges]. Med Sante Trop. 2015;25(4):342-349.
Batina Agasa S, Dupont E, Kayembe T, et al. Multiple transfusions for sickle cell disease in the Democratic Republic of Congo: the importance of the hepatitis C virus. Transfus Clin Biol. 2010;17(4):254-259.
Tonen-Wolyec S, Batina-Agasa S, Muwonga J, Mboumba-Bouassa RS, Tshilumba CK, Bélec L. Acceptability, feasibility, and individual preferences of blood-based HIV self-testing in a population-based sample of adolescents in Kisangani, Democratic Republic of the Congo. PLoS One. 2019;14(7):e0218795.
Agasa B, Bosunga K, Opara A, et al. Prevalence of sickle cell disease in a northeastern region of the Democratic Republic of Congo: what impact on transfusion policy? Transfus Med. 2010;20(1):62-65.
Steele C, Sinski A, Asibey J, et al. Point-of-care screening for sickle cell disease in low-resource settings: a multi-center evaluation of Hemo Type SC, a novel rapid test. Am J Hematol. 2019;94(1):39-45.
Segbena AY, Guindo A, Buono R, et al. Diagnostic accuracy in field conditions of the sickle SCAN® rapid test for sickle cell disease among children and adults in two west African settings: the DREPATEST study. BMC Hematol. 2018;18:26.
Olujohungbe A, Hambleton I, Stephens L, Serjeant B, Serjeant G. Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol. 2001;113(3):661-665.
Sins JW, Biemond BJ, van den Bersselaar SM, et al. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Am J Hematol. 2016;91(8):763-769.
Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773-2781.
Campbell-Lee SA, Kittles RA. Red blood cell alloimmunization in sickle cell disease: listen to your ancestors. Transfus Med Hemother. 2014;41(6):431-435.
Mijovic A, Perera IG, Thein SL. Red blood cell alloimmunization in sickle cell disease-prevalence and trends: a single-center cross-sectional study from United Kingdom. Transfusion. 2013;53(12):3279-3280.
Allali S, Peyrard T, Amiranoff D, et al. Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference Centre. Br J Haematol. 2017;177(4):641-647.
Zheng Y, Maitta RW. Alloimmunisation rates of sickle cell disease patients in the United States differ from those in other geographical regions. Transfus Med. 2016;26(3):225-230.
Compernolle V, Chou ST, Tanael S, et al. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. Transfusion. 2018;58(6):1555-1566.
Pirenne F, Floch A, Habibi A. How to avoid the problem of erythrocyte alloimmunization in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2021;2021(1):689-695.
Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized SCD patients: a survey of 1182 north American laboratories. Arch Pathol Lab Med. 2005;129:190-193.
Klinkenberg EF, Huis In't Veld EMJ, de Wit PD, et al. Blood donation barriers and facilitators of sub-Saharan African migrants and minorities in Western high-income countries: a systematic review of the literature. Transfus Med. 2019;29(Suppl 1):28-41.
Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell Alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfus Med Rev. 2019;33(3):162-169.
Schonewille H, van de Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion. 2006;46(2):250-256.
Agasa SB, Mango BM, Bome LB, Basandja JO, Kombi PK, Tshilumba CK. Blood group phenotype frequencies in blood donors in the northeast of Democratic Republic of Congo. IBRR. 2017;7(2):1-5.
Touinssi M, Chapel-Fernandes S, Granier T, Bokilo A, Bailly P, Chiaroni J. Molecular analysis of inactive and active RHD alleles in native Congolese cohorts. Transfusion. 2009;49(7):1353-1360.
Reid ME, Lomas-Francis C, Olsson ML. Ok blood group system. The Blood Group Antigen Facts Book. Fird ed. Academic Press, New York; 2012.
فهرسة مساهمة: Keywords: alloimmunisation; blood transfusion; prevalence; sickle cell disease
المشرفين على المادة: 0 (Isoantibodies)
0 (Blood Group Antigens)
تواريخ الأحداث: Date Created: 20221115 Date Completed: 20230404 Latest Revision: 20230404
رمز التحديث: 20240628
DOI: 10.1111/tme.12939
PMID: 36377544
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-3148
DOI:10.1111/tme.12939